Table 1. Characteristics of included studies - TENS

Study	Participants (number, age, other important characteristics)	Comparison	Follow-up	Outcome measures	Comments	Risk of bias (per outcome measure)*
Celik, 2013 *RCT, Turkey*	**N at baseline** Intervention: 17 Control: 16 **Age (mean, SD)** Intervention: 38.2 (9.9) years Control: 34.8 (10.9) years **Sex (% female)** Intervention: 23.5% Control: 31.3% **Mean time after injury (range)** 24.1 (2-27) months[#] **Mean LANSS (SD)** 16.9 (2.5)[#]	Intervention: **Low frequency TENS** *Pulse frequency 4 Hz, pulse duration 200□s, pulse amplitude 50 mA.* *30-minutes sessions for 10 days.* Control: **Sham TENS** *Electrodes placed, no stimulation. 30-minutes sessions for 10 days.* *All participants were prescribed to take 10 mg of amitriptyline daily for at least 15 days before treatment.*	12 days of which 10 days of treatment.	Pain Complications	No funding source has been reported. The authors declare no conflict of interest.	High for all outcome measures.

Vitalii, 2014 *RCT, Moldova*	**N at baseline** Intervention: 11 Control: 10 **Age (mean, SD)** Intervention: 31.7 (7.7) years Control: 28.9 (6.1) years **Sex (% female)** Intervention: 9.1% Control: 10% **Mean time after injury (range)** 16.0 (1-35) months[#] **Mean LANSS (SD)** 16.0 (1.85)[#]	Intervention: **Low frequency TENS + gabapentin** *Pulse frequency 4 Hz, pulse duration 200 s, pulse amplitude 50 mA.* *30-minutes sessions for 10 days.* *Increasing dose of gabapentin (300-900 mg).* Control: **Sham TENS + gabapentin** *Electrodes placed, no stimulation. 30-minutes sessions for 10 days.* *Increasing dose of gabapentin (300-900 mg).*	10 days of treatment.	Pain Complications	No funding source has been reported. No conflict of interest reported.	High for all outcome measures.

Abbreviations: LANSS = leeds assessment of neuropathic symptoms and signs; NR = not reported; RCT = randomized controlled trial; SCI = spinal cord injury; SD = standard deviation; TENS = transcutaneous electric nerve stimulation.
****For further details, see risk of bias table in the appendix***
[#]Reported for the total study population only